Recent News

• 01.28.2025 - Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
• 01.22.2025 - Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
• 01.21.2025 - Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
• 12.23.2024 - Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Recent Filings

• 01.31.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.31.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.31.2025 - EFFECT Notice of Effectiveness
• 01.31.2025 - EFFECT Notice of Effectiveness
• 01.30.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 01.30.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 01.28.2025 - 8-K Current report
• 01.28.2025 - EX-99.1 EX-99.1
• 01.22.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 01.22.2025 - S-1 General form for registration of securities under the Securities Act of 1933